DA 6650

Drug Profile

DA 6650

Alternative Names: DA-6650

Latest Information Update: 22 Aug 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dong-A Pharmaceutical
  • Class Anti-inflammatories; Benzamides; Irritable bowel syndrome therapies; Small molecules
  • Mechanism of Action Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Dyspepsia; Gastro-oesophageal reflux; Irritable bowel syndrome

Most Recent Events

  • 06 Nov 2011 No development reported - Phase-I for Dyspepsia in South Korea (PO)
  • 06 Nov 2011 No development reported - Phase-I for Gastro-oesophageal reflux in South Korea (PO)
  • 06 Nov 2011 No development reported - Phase-I for Irritable bowel syndrome in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top